Cerexa
Cerexa was a privately held biopharmaceutical company founded in the mid-2000s (its cerexa.com domain was registered in March 2005) to develop anti-infective therapies for serious, drug-resistant bacterial infections in the hospital setting. Its lead program was ceftaroline fosamil, a fifth-generation cephalosporin antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA), in-licensed from Takeda Pharmaceutical Company and carried forward by Forest Laboratories; the compound was approved by the FDA on October 29, 2010 and marketed as Teflaro in the United States and Zinforo in Europe. Cerexa was backed by venture investors including Canaan Partners, and its programs ultimately passed through Forest Laboratories into the Actavis/Allergan combination (Forest Laboratories was acquired by Actavis on July 1, 2014) and on to AbbVie. Cerexa no longer operates as an independent company and has no developer surface: it publishes no API, no SDKs, no GitHub organization and no documentation, and its historical cerexa.com domain is now registered and operated by AbbVie, 301-redirecting to AbbVie's Allergan page. This profile is retained as a historical company record in the API Evangelist network.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles Cerexa the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — Cerexa scores 7.7/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile Cerexa
Each block below is one kind of artifact we hold for Cerexa. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for Cerexa — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
← All providers · Data indexed from github.com/api-evangelist/cerexa · machine-readable index on apis.io